Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice

Gene Therapy

Volumn 3, Issue 8, 1996, Pages 706-716

  Lochmuller H ^a   Petrof, B J ^b,c   Pari, G ^a   Larochelle, N ^a   Dodelet, V ^a   Wang, Q ^a   Allen, C ^a   Prescott, S ^a   Massie, B ^d   Nalbantoglu, J ^a   Karpati, G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adenovirus; Dystrophin; FK506 immunosuppression; Gene transfer; Muscular dystrophy

Indexed keywords

DYSTROPHIN; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE SYNTHASE; TACROLIMUS;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSTROPHY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; DYSTROPHIN; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOCOMPETENCE; IMMUNOSUPPRESSION; MICE; MICE, INBRED MDX; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; TACROLIMUS; TIME FACTORS; TRANSGENES;

ADENOVIRIDAE; ANIMALIA;

EID: 0029741231     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Acsadi G et al. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Gen 1994; 3: 579-584.
2. Acsadi G et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther 1996; 7: 129-140.
3. Quantin B, Perricaudet L, Tajbakhsh S, Mandel L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992; 89: 2581-2584.
4. Dai Y et al. Cellular and humoral immune response to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Nutl Acad Sci USA 1995; 92: 1401-1405.
5. Van Ginkel F et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther 1995; 6: 895-903.
6. Yang Y, Trinchieri G, Wilson J. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995; 1: 890-893.
7. Kay M et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
8. Fang B et al. Gene therapy for hemophilia B: host immunosuppression prolongs therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
9. Lochmüller H et al. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic (mdx) mice. Biochem Biophys Res Commun 1995; 213: 569-574.
10. Vilquin J et al- FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
11. Murase N et al. Suppression of allograft rejection with FK506. Transplantation 1990; 50: 186-189.
12. McDiarmid S et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver trans-plantation. Transplantation 1995; 59: 530-536.
13. Kinoshita I et al. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 1994; 17: 1407-1415.
14. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797-1803.
15. Schreiber S, Crabtree G. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142.
16. Andersson J, Nagy S, Groth C, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single cell level. Immunology 1992; 75: 136-142.
17. Conde M et al. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology 1995; 84: 476-481.
18. Haddad I et al. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994; 94: 2407-2413.
19. Vilquin J et al. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 1995; 131: 975-988.
20. McCoy R et al. Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: effects on vector-induced inflammation. Gene Therapy 1995; 2: 437-442.
21. Coutelier J-P, Broeck J, Wolf S. Interleukin-12 gene expression after viral infection in the mouse. J Viral 1995; 69: 1955-1958.
22. Ginsberg H et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 1991; 88: 1651-1655.
23. Harms J, Splitter G. Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHCI promoter. Hum Gene Ther 1995; 6: 1291-1297.
24. Durham H et al. Toxicity of replication-defective adenoviral recombinants in dissociated cultures of nervous tissue. Exp Neural (in press).
25. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
26. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
27. Takada K et al. Pharmacokinetics of FK-506, a novel immuno-suppressant, after intravenous and oral administration to rats. J Pharmacobio-Dyn 1991; 14: 34-42.
28. Morris R et al. Immunopharmacology of FK-506. Transplant Proc 1989; 21: 1042-1044.
29. Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo. Transplant 1990; 50: 272-277.
30. Gardner-Medwin D, Walton J. Clinical problems in neuromuscular disease: the muscular dystrophies. In: Walton J, Karpati G, Hilton-Jones D (eds). Disorders of Voluntary Muscle. Churchill-Livingstone: New York, 1994, pp 549-560.
31. Lochmüller H et al. Emergence of early region 1 (E1)-containing replication competent adenovirus in stocks of replication defective adenovirus recombinants (ΔE1+ΔE3) during multiple passages in 293 cells. Hum Gene Ther 1994; 5: 1485-1491.